ACADIA PHARMACEUTICALS INC. Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months
ACADIA PHARMACEUTICALS INC. (ACAD) had Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months of $400.00 thousand as of 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths · last filed 2021-08-05
- 2021-06-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $400.00K.
- 2021-03-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $700.00K.
- 2020-12-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $1.10M.
- 2020-09-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $1.10M.
| Period end | Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months |
|---|---|
| 2021-06-30 | $400.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $700.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | $1.10M 10-K · filed 2021-02-25 |
| 2020-09-30 | $1.10M 10-Q · filed 2020-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |